Diagnosing Frontotemporal Lobar Degeneration

University Health Network, Toronto100 enrolled

Overview

To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes

The goal of this study is to determine the best diagnostic test for diagnosing frontotemporal lobar degeneration. To accomplish this, the current study will evaluate different tests: brain imaging, skin biopsy, body fluid samples (blood and cerebrospinal fluid), thinking abilities, everyday functioning, and brain autopsy. The study team hopes that this information can be used to guide diagnosis and further understanding of mechanism of disease in Frontotemporal Lobar Degeneration and possibly treatment in the future.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Corticobasal Syndrome Progressive Supranuclear Palsy Behavioral Variant Frontotemporal Dementia Semantic Dementia Progressive Nonfluent Aphasia Amyotrophic Lateral Sclerosis And/or Frontotemporal Dementia

Interventions

Observational StudyOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Participant must have a reliable study partner who can provide an independent evaluation of functioning. * Able to read, understand and speak English for neuropsychological testing. * All subjects must meet one of these diagnostic criteria (A) probable behavioral variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic variant PPA and \[18F\]T807 negative (D) probable CBS: using current criteria for CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy (NINDS-SPSP) (F) FTD-MND * Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and MMSE score equal to or greater than 28 Exclusion Criteria: * Patients with clinical, imaging or CSF A beta/ tau profile consistent with AD * History of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded. * Premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from PET study. * Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.

Locations (1)

Toronto Western Hospital, University Health Network

Toronto, Ontario, Canada

RECRUITING

Outcomes

Primary Outcomes

Structural and Functional Diffferences between the FTLD groups via MRI of the brain

Differences in brain volumes and resting state functional connectivity

Time frame: One time visit through study completion of 5 years

Differences between the FTLD groups via PET imaging of the brain

Differences in ligand uptake

Time frame: One time visit through study completion of 5 years

Central Contacts

Cristina Salvo, BSc, MD

CONTACT

416-507-6880 cristina.salvo@uhn.ca

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.